This text is reproduced from Chapter 34 of GI Epidemiology, Nicholas J. Talley, G. Richard Locke III and Yuri A. Saito, editors. Blackwell Publishing Ltd: UK Publication date: May 2007; ISBN: 9781405149495 http://www.blackwellgastroenterology.com/9781405149495.
GI Epidemiology: nonalcoholic fatty liver disease
Version of Record online: 30 MAR 2007
Alimentary Pharmacology & Therapeutics
Volume 25, Issue 8, pages 883–889, April 2007
How to Cite
ANGULO, P. (2007), GI Epidemiology: nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 25: 883–889. doi: 10.1111/j.1365-2036.2007.03246.x
- Issue online: 30 MAR 2007
- Version of Record online: 30 MAR 2007
Background Nonalcoholic fatty liver disease (NAFLD) is a common diagnosis in clinical practice. Insulin resistance and oxidative stress play an important role in NAFLD development and progression.
Aim To review the data available on the epidemiology and natural history of NAFLD as well as the risk factors for its development and the areas where future research is necessary.
Results/Conclusions NAFLD may affect individuals of any age range and race/ethnicity. NAFLD affects one in three adults and one in ten children/adolescents in the United States. Mortality in patients with NAFLD is significantly higher than in the general population of same age and gender with liver-related complications being a common cause of death. Liver-related morbidity and mortality in NAFLD occurs when the disease has progressed to advanced fibrosis and cirrhosis. Further studies are necessary to determine the impact of NAFLD on health-related quality of life and resources utilization, and to the extent to which preventing the development of the metabolic syndrome would prevent NAFLD development and reduce liver-related morbidity and mortality. Lifestyle intervention may improve NAFLD, but medications that increase insulin sensitivity and the antioxidant defenses in the liver deserve evaluation in carefully controlled trials.